RhumbLine Advisers’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-805
| Closed | -$1.02K | – | 4319 |
|
|
2023
Q3 | $1.02K | Hold |
805
| – | – | ﹤0.01% | 4180 |
|
|
2023
Q2 | $262 | Buy |
+805
| New | +$289 | ﹤0.01% | 4346 |
|
|
2020
Q2 | – | Sell |
-21,505
| Closed | -$82K | – | 3131 |
|
|
2020
Q1 | $82K | Hold |
21,505
| – | – | ﹤0.01% | 2812 |
|
|
2019
Q4 | $130K | Buy |
21,505
+624
| +3% | +$4.27K | ﹤0.01% | 2846 |
|
|
2019
Q3 | $158K | Buy |
20,881
+881
| +4% | +$9.93K | ﹤0.01% | 2803 |
|
|
2019
Q2 | $271K | Buy |
+20,000
| New | +$231K | ﹤0.01% | 2649 |
|
|
2018
Q2 | – | Sell |
-10,577
| Closed | -$92K | – | 2938 |
|
|
2018
Q1 | $92K | Buy |
10,577
+240
| +2% | +$2.59K | ﹤0.01% | 2753 |
|
|
2017
Q4 | $129K | Sell |
10,337
-7,252
| -41% | -$83.1K | ﹤0.01% | 2739 |
|
|
2017
Q3 | $147K | Buy |
17,589
+3,906
| +29% | +$41.3K | ﹤0.01% | 2823 |
|
|
2017
Q2 | $232K | Buy |
+13,683
| New | +$272K | ﹤0.01% | 2690 |
|
RhumbLine Advisers's ZYNE Position: Q4 2023 in Review
RhumbLine Advisers sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 805 shares — an estimated $1.02K sold.
RhumbLine Advisers first reported a position in ZYNE in Q2 2017 and held it in 10 quarters. The position peaked at $271K in Q2 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- RhumbLine Advisers reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- RhumbLine Advisers sold 805 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $1.02K.
- RhumbLine Advisers first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 10 quarters.
- RhumbLine Advisers's Zynerba Pharmaceuticals, Inc position peaked at $271K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.